tiprankstipranks
Trending News
More News >
Lixte Biotechnology Holdings (LIXT)
NASDAQ:LIXT
Advertisement

Lixte Biotechnology Holdings (LIXT) Price & Analysis

Compare
88 Followers

LIXT Stock Chart & Stats


Lixte Biotechnology Holdings News

LIXT FAQ

What was Lixte Biotechnology Holdings’s price range in the past 12 months?
Lixte Biotechnology Holdings lowest stock price was $0.64 and its highest was $4.88 in the past 12 months.
    What is Lixte Biotechnology Holdings’s market cap?
    Lixte Biotechnology Holdings’s market cap is $14.10M.
      When is Lixte Biotechnology Holdings’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Lixte Biotechnology Holdings’s earnings last quarter?
      Currently, no data Available
      Is Lixte Biotechnology Holdings overvalued?
      According to Wall Street analysts Lixte Biotechnology Holdings’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Lixte Biotechnology Holdings pay dividends?
        Lixte Biotechnology Holdings does not currently pay dividends.
        What is Lixte Biotechnology Holdings’s EPS estimate?
        Lixte Biotechnology Holdings’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Lixte Biotechnology Holdings have?
        Lixte Biotechnology Holdings has 2,894,749 shares outstanding.
          What happened to Lixte Biotechnology Holdings’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Lixte Biotechnology Holdings?
          Currently, no hedge funds are holding shares in LIXT

          Company Description

          Lixte Biotechnology Holdings

          Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.

          Lixte Biotechnology Holdings (LIXT) Earnings & Revenues

          Currently, no data available
          Please return soon. This page is being updated.
          Similar Stocks
          Company
          Price & Change
          Follow
          Ibio
          Windtree Therapeutics
          BiomX
          Bolt Biotherapeutics
          Acurx Pharmaceuticals

          Ownership Overview

          4.62%0.75%4.99%89.46%
          4.62%
          Insiders
          4.99% Other Institutional Investors
          89.46% Public Companies and
          Individual Investors

          Options Prices

          Currently, No data available
          ---
          Popular Stocks
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis